Update on Relapsed SCLC Monotherapy Trial | Overall Survival Data of 11.8 Months. w Lurbinectedin Fix

Pascal Besman, Chief Operating Officer of PharmaMar, shares an Update on Relapsed SCLC Monotherapy Trial | Overall Survival Data of 11.8 Months. w Lurbinectedin Fix at Annual Meeting 2018